AIMT Aimmune Therapeutics Inc.

22.79
+0.02  (+0%)
Previous Close 22.77
Open 22.75
Price To Book 6.97
Market Cap 1,428,332,067
Shares 62,668,957
Volume 146,435
Short Ratio
Av. Daily Volume 955,962

NewsSee all news

  1. FDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmune's PALFORZIA™ (AR101) for Peanut Allergy

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Allergenic Products Advisory Committee (APAC)

  2. Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting to Discuss PALFORZIA™ (AR101) for Peanut Allergy

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that NASDAQ has halted trading of the company's common stock. The U.S.

  3. Biotech Brief: Latest Electrophysiology Devices Vastly Improving Diagnosis and Treatment of Cardiovascular Diseases

    PALM BEACH, Fla., Sept. 12, 2019 (GLOBE NEWSWIRE) -- According to a recent market research report published by Grand View Research, a consulting and advisory service firm that provides comprehensive, research-based

  4. Aimmune to Participate in Three Investor Conferences in September

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial met primary endpoint - March 25, 2019.
AR101 ARTEMIS
Peanut Allergy
Phase 3 data released November 8, 2018 noted no serious adverse events
AR101 RAMSES
Peanut Allergy
PDUFA date late-January 2020. Advisory Committee meeting September 13, 2019 voted in favor of supporting approval.
AR101
Peanut Allergy
Phase 2 initiation of enrolment announced August 21, 2019.
AR 201
Egg Allergy
Phase 2 trial initiation announced October 15, 2018.
AR101 with adjunctive dupilumab
Peanut Allergy
Phase 3 data due 2020.
AR101 POSEIDON
Peanut Allergy

Latest News

  1. FDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmune's PALFORZIA™ (AR101) for Peanut Allergy

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Allergenic Products Advisory Committee (APAC)

  2. Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting to Discuss PALFORZIA™ (AR101) for Peanut Allergy

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that NASDAQ has halted trading of the company's common stock. The U.S.

  3. Biotech Brief: Latest Electrophysiology Devices Vastly Improving Diagnosis and Treatment of Cardiovascular Diseases

    PALM BEACH, Fla., Sept. 12, 2019 (GLOBE NEWSWIRE) -- According to a recent market research report published by Grand View Research, a consulting and advisory service firm that provides comprehensive, research-based

  4. Aimmune to Participate in Three Investor Conferences in September

    Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in